Ovid Therapeutics Inc.
OVID· Nasdaq
Released Aug 9, 2022, before the open
10-Q filed Aug 9, 2022, 40 days after period end · 0001628280-22-021759
| Metric | Q2 2022 | Q2 2021 | Q2 2020 | Q2 2019 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — |
| Net Income | -$14.59M | -$15.79M | -$22.55M | -$13.06M |
| EPS Diluted |
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
| -$0.21 |
| -$0.23 |
| -$0.41 |
| -$0.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.